Genetic Technologies Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Genetic Technologies.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Life Sciences earnings growth | 17.0% |
Revenue growth rate | n/a |
Future return on equity | n/a |
Analyst coverage | None |
Last updated | n/a |
Recent future growth updates
No updates
Recent updates
Genetic acquires AffinityDNA to bolster direct-to-consumer business
Jul 14Infinity Biologix launches Genetic Technologies' COVID-19 test
Jun 09Genetic Technologies launches COVID-19 risk test through partnership with Infinity Biologix
Jun 01Genetic Technologies’ COVID-19 risk test to be commercially available in U.S.
Apr 26Genetic Technologies appoints new CEO; Shares are up 8%
Jan 04In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Genetic Technologies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2023 | 10 | -13 | -8 | -8 | N/A |
9/30/2023 | 10 | -12 | -9 | -9 | N/A |
6/30/2023 | 10 | -12 | -10 | -10 | N/A |
3/31/2023 | 11 | -10 | -9 | -9 | N/A |
12/31/2022 | 11 | -9 | -8 | -8 | N/A |
9/30/2022 | 10 | -8 | -7 | -7 | N/A |
6/30/2022 | 9 | -7 | -6 | -6 | N/A |
3/31/2022 | 7 | -7 | -6 | -6 | N/A |
12/31/2021 | 5 | -7 | -7 | -7 | N/A |
9/30/2021 | 3 | -7 | -7 | -6 | N/A |
6/30/2021 | 1 | -7 | -7 | -6 | N/A |
3/31/2021 | 2 | -7 | -7 | -6 | N/A |
12/31/2020 | 0 | -7 | -7 | -7 | N/A |
9/30/2020 | 0 | -7 | -6 | -6 | N/A |
6/30/2020 | 1 | -6 | -6 | -6 | N/A |
3/31/2020 | 0 | -6 | -6 | -5 | N/A |
12/31/2019 | 0 | -6 | -5 | -5 | N/A |
9/30/2019 | 0 | -6 | -6 | -6 | N/A |
6/30/2019 | 0 | -6 | -6 | -6 | N/A |
3/31/2019 | 0 | -6 | -6 | -6 | N/A |
12/31/2018 | 0 | -5 | -6 | -6 | N/A |
9/30/2018 | 0 | -5 | -6 | -6 | N/A |
6/30/2018 | 0 | -5 | -6 | -6 | N/A |
3/31/2018 | 0 | -7 | -6 | -6 | N/A |
12/31/2017 | 0 | -8 | -7 | -6 | N/A |
9/30/2017 | 0 | -8 | N/A | -7 | N/A |
6/30/2017 | 1 | -8 | N/A | -7 | N/A |
3/31/2017 | 1 | -8 | N/A | -7 | N/A |
12/31/2016 | 1 | -8 | N/A | -7 | N/A |
9/30/2016 | 1 | -8 | N/A | -7 | N/A |
6/30/2016 | 1 | -8 | N/A | -8 | N/A |
3/31/2016 | 1 | -8 | N/A | -8 | N/A |
12/31/2015 | 1 | -8 | N/A | -8 | N/A |
9/30/2015 | 2 | -9 | N/A | -9 | N/A |
6/30/2015 | 2 | -9 | N/A | -10 | N/A |
3/31/2015 | 3 | -9 | N/A | -11 | N/A |
12/31/2014 | 4 | -10 | N/A | -12 | N/A |
9/30/2014 | 4 | -10 | N/A | -11 | N/A |
6/30/2014 | 5 | -10 | N/A | -11 | N/A |
3/31/2014 | 4 | -10 | N/A | -10 | N/A |
12/31/2013 | 4 | -11 | N/A | -10 | N/A |
9/30/2013 | 4 | -10 | N/A | -9 | N/A |
6/30/2013 | 3 | -9 | N/A | -8 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if GENE's forecast earnings growth is above the savings rate (2.3%).
Earnings vs Market: Insufficient data to determine if GENE's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if GENE's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if GENE's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if GENE's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if GENE's Return on Equity is forecast to be high in 3 years time